This study was focused on the synthesis and in vitro anti-toxoplasma activity evaluation of eight new trithiolato-bridged arene-ruthenium(II) carbohydrate conjugates. Acetyl protected glucose and galactose moieties were pended on the diruthenium unit on one of the bridging thiols using CuAAC 'click' reactions and connectors of diverse types and lengths to obtain the carbohydrate-dyads. In the first screening, none of the conjugates affected the validity of host cells at 1 µM, suggesting reduced toxicity, and seven of the eight carbohydrate-diruthenium hybrids applied at 1 µM inhibited T. gondii β-gal growth by more than 90%. The second screening (IC50 values and toxicity to HFFs after exposure to 2.5 µM) led to the identification of two very promising acetyl protected galactose functionalized compounds 23 and 26. Both conjugates not only highly exceeded (up to 10-fold) the anti-toxoplasma efficacy of the standard drug pyrimethamine for similar level of toxicity to HFF, but also had a significantly better balance antiparasitic activity/cytotoxicity compared to the corresponding noncarbohydrate tagged diruthenium complexes.